For 14 years, scientists have been growing a tree akin to the Judean balsam — the source of the balm of Gilead — but with ... director of natural medicine research at the Hadassah Hospital ...

Horticulturists are celebrating the growth of a 1,000 year old “Tsori” seed, discovered nearly 30 years ago, which is ...

Gilead said Tuesday that it will soon begin Phase 3 testing for a drug it believes could prevent HIV infection with just a single shot every year. Such a medicine, if proven effective, would be ...

In September, Gilead revealed the results of an interim analysis from a second Phase 3 trial investigating the use of the company’s twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir.

Gilead (GILD) announced that Dietmar Berger will join the company on January 2, 2025, as Chief Medical Officer and will become a member of Gilead’s senior leadership team. Berger succeeds Merdad ...

Looking ahead, once-yearly HIV prevention injections could be on the horizon, Gilead Sciences executives said at a December 10 analyst and investor event. The drug, however, is not yet approved for ...

Gilead Sciences will no longer provide four HIV medicines for free as part of a patient assistance program starting at the end of January, alarming community activists who worry the move will ...

Gilead Sciences said a key European regulatory committee recommended expanded approval of its seladelpar treatment for patients with primary biliary cholangitis, a chronic and progressive liver ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results from the company’s pivotal Phase 3 PURPOSE 2 trial evaluating twice ...